Kuiper Babette I, Pilz da Cunha Gabriela, Arntz Pieter J W, Bennink Roel J, Zonderhuis Barbara M, van Delden Otto M, Kazemier Geert, Erdmann Joris, Besselink Marc G, Meijerink Martijn R, Swijnenburg Rutger-Jan
Department of Surgery, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
J Gastrointest Surg. 2025 Sep;29(9):102158. doi: 10.1016/j.gassur.2025.102158. Epub 2025 Jul 16.
Two-stage hepatectomy (TSH) expands local treatment options in patients with extensive bilobar liver tumors. The success of TSH depends on rapid recovery after first-stage treatment, effective hypertrophy induction, and precise functional liver remnant function assessment to minimize the risk of posthepatectomy liver failure (PHLF). This study aimed to assess the safety and efficacy of minimally invasive left-sided local liver treatment with or without partial associated liver partition and portal vein ligation for staged hepatectomy (pALPPS) or pALPPS alone combined with same-admission right portal vein embolization (PVE) and routine assessment of liver function using hepatobiliary scintigraphy (HEBIS).
This retrospective cohort study included all patients who underwent minimally invasive left-sided liver resection, ablation, or pALPPS alone followed by same-admission PVE as the first stage of TSH at the Amsterdam University Medical Center between 2015 and 2022. Perioperative outcomes were assessed.
In 20 patients, minimally invasive first-stage left liver resection and/or ablation or pALPPS alone was performed for colorectal liver metastases (n = 17), hepatocellular carcinoma (n = 2), and cholangiocarcinoma (n = 1), with pALPPS in 11 patients. Subsequently, 19 patients underwent same-admission PVE, with a median time to PVE of 2 days (IQR, 1-4). Of note, 2 patients (10%) experienced Clavien-Dindo grade ≥ IIIa complications after the first stage treatment. The median hospital stay was 5 days (IQR, 3-4). Ultimately, 14 patients (70%) underwent second-stage (extended) right hemihepatectomy with no grade B/C PHLF or 90-day mortality.
Minimally invasive first-stage resection combined with same-admission PVE and routine HEBIS is safe and feasible and yields excellent outcomes, including 70% second-stage hepatectomies and no 90-day mortality. Larger multicenter studies should be conducted to confirm the findings.
两阶段肝切除术(TSH)扩大了广泛双侧肝肿瘤患者的局部治疗选择。TSH的成功取决于一期治疗后的快速恢复、有效的肥大诱导以及精确的功能性肝残余功能评估,以将肝切除术后肝衰竭(PHLF)的风险降至最低。本研究旨在评估微创左侧局部肝治疗联合或不联合部分相关肝分隔及门静脉结扎分期肝切除术(pALPPS)或单独pALPPS联合同期右门静脉栓塞术(PVE)并使用肝胆闪烁显像(HEBIS)进行肝功能常规评估的安全性和有效性。
这项回顾性队列研究纳入了2015年至2022年期间在阿姆斯特丹大学医学中心接受微创左侧肝切除、消融或单独pALPPS作为TSH第一阶段并同期进行PVE的所有患者。评估围手术期结果。
20例患者因结直肠癌肝转移(n = 17)、肝细胞癌(n = 2)和胆管癌(n = 1)接受了微创一期左侧肝切除和/或消融或单独pALPPS,其中11例患者接受了pALPPS。随后,19例患者接受了同期PVE,PVE的中位时间为2天(IQR,1 - 4)。值得注意的是,2例患者(10%)在一期治疗后出现Clavien - Dindo≥IIIa级并发症。中位住院时间为5天(IQR,3 - 4)。最终,14例患者(70%)接受了二期(扩大)右半肝切除术,无B/C级PHLF或90天死亡率。
微创一期切除联合同期PVE和常规HEBIS是安全可行的,并且能产生优异的结果,包括70%的二期肝切除术和无9